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Study design: The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to an-
tihypertensive drugs used asmono- or dual therapy on the basis of self-defined ethnicity. Amulticenter, prospective,
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103O. Mukhtar et al. / American Heart Journal 204 (2018) 102–108lisinopril 20mgod; amlodipine 5mgod and chlorthalidone 25mg od; lisinopril 20mgod and chlorthalidone 25mg
od; amiloride 10mgod and chlorthalidone 25mgod), 4-period crossover, lasting 32weeks. Equal numbers of 3 eth-
nic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms
(ie, 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure mea-
sured 8 weeks after each treatment period begins will serve as the primary outcome measure.
Conclusion:AIM-HY INFORM is a prospective, open-label, randomized trialwhich aims to evaluate first- and second-
line antihypertensive therapies for multiethnic populations.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Trial objectives
Primary objective
- To determine whether the response to antihypertensive drugs differs on the basis
of SDE
Secondary objectives
- To determine if the response to antihypertensive drugs differs by:
- AIMs
- Baseline metabolomics
- Baseline hemodynamics
- Genomics
- Detailed SDE (family tree extending to grandparents)
- To compare detailed SDE with AIMs as a cause for the response to
antihypertensive drugs
- To determine the most effective mono- and dual therapy for hypertension and
whether this varies by ethnicity
- To determine whether metabolomics and hemodynamics differ by ethnicity
- To test whether previously identified biomarkers (derived from other cohorts, eg,
United States) can predict drug responseHypertension is the single biggest contributor to the global burden
of disease, a burden that is particularly great in lower- and middle-
income countries.1 In high-income economies, ethnic minorities—
often originating from lower- and middle-income countries—also
appear to be disproportionately affected when compared to indigenous
populations.2-4 Complex interactions between genes and the environ-
ment are thought to influence the pathophysiology of essential hyper-
tension, the frequency of hypertension-related complications, and the
response to treatment.1 However, data relating to ethnicity are compli-
cated by the plethora of methods used to define ethnicity or race, and a
greater understanding of environmental influences has led to the recog-
nition that data collected in one country may not be readily applicable
to similar ethnic groups in distinct geographical locations.1
European guidelines relating to the management of arterial hyper-
tension make no allowance for ethnicity.5 In contrast, the North
American guideline, published by the Joint National Committee in
2014, does, stating, “In the general black population, including those
with diabetes, initial antihypertensive treatment should include a
thiazide-type diuretic or CCB [calcium channel blocker].”6 Stratified by
age and self-defined ethnicity (SDE), the UK's National Institute for
Health and Care Excellence (NICE) recommends a third approach,
with distinct initial monotherapies recommended for all those aged 55
years and over, as well as for younger black adults when compared to
whites.7 However, the guideline makes no reference to South Asians
(ie, those originating from the Indian subcontinent)—despite the fact
that they represent the largest ethnic minority group in the United
Kingdom at 4.7 million people (52.5 million “white British” citizens
being the largest group within a total population of 65.6 million
people).7,8 Furthermore, the aforementioned guidelines fail to extend
stratification to combination therapy.5-7
Stratification on the basis of SDE is potentially flawed by virtue of an
increasingly “admixed” population, the complex relationship between
ethnicity and phenotype, and its inherent cohort-based approach which
fails to account for interindividual variations.9 An alternative method of
stratification seeks to use ancestry informative markers (AIMs)—genetic
polymorphisms occurring with substantially different frequencies across
populations from distinct geographical regions. Able to predict geograph-
ical ancestry, AIMs may capture the genetic component responsible for
variations in drug response among ethnically diverse populations more
discerningly than SDE.9,10 Concurrent metabolomic profiling of plasma
and urine (measurement of low– and intermediate–molecular weight
metabolites which reflect the complex interplay between genetic, physi-
ological, pathophysiological, and/or environmental factors) offers the po-
tential to augment AIMs, with differences between individuals reflecting
the entire spectrum of influences, especially diet.11,12
In an effort to address these issues, the AIM-HY INFORM trial intends
to compare variations in response to antihypertensive agents among 3
cohorts of the UKpopulation stratified on the basis of SDE,while also re-
lating any variations to AIMs and metabolomic profiles. In doing so, we
hope to evaluate the validity of current NICE guidance which has SDE at
the center of its approach to pharmacotherapy and to examinewhether
use of AIMs and/or metabolomic profiling results in the more effective
personalization of antihypertensive treatment. Furthermore, the trial
will evaluate the efficacy of both monotherapy and dual therapy across
all 3 cohorts and try to elucidate potential mechanisms underlying anydifference in outcomes achieved by using SDE and AIMs. Thus, AIM-HY
INFORMwill enable clinicians to optimize their choice of antihyperten-
sive treatments from current, generic, first- and second-line agents, re-
ducing the attrition of antihypertensive therapies.
Hypotheses
We hypothesize that the response to antihypertensive drugs (used
either as mono- or dual therapy) differs by ethnicity.
Our secondary hypothesis relates to the possibility that AIMs and
metabolites, and/or baseline hemodynamic measurements, are able to
predict response to antihypertensive therapy.
Methods
Study design and objectives
AIM-HY INFORM is a multicenter, prospective, open-label study
with 2 parallel, independent trial arms (mono- and dual therapy).
Eleven UK sites will enroll a total of 1,320 patients. Those receiving
monotherapy (n = 660) will enter a 3-treatment, 3-period crossover,
lasting 24 weeks, whereas those receiving dual therapy (n = 660) will
enter a 4-treatment, 4-period crossover, lasting 32 weeks. Equal num-
bers of all 3 ethnic groups (white, black/black British, and Asian/Asian
British)will ultimately be recruited to each of the trial arms (ie, 220 par-
ticipants per ethnic group per arm).
The primary objective of the AIM-HY INFORM trial is to determine
whether the response to antihypertensive drugs differs on the basis of
SDE. Secondary objectives (Table I) include an evaluation of this re-
sponse on the basis of AIMs, baseline metabolomics, baseline hemody-
namic data, genomics, and a more detailed evaluation of SDE (with a
family tree extending to 3 generations, ie, grandparents). Additionally,
the trial aims to determine (1) the most effective mono- and dual ther-
apy for hypertension and any variation(s) by ethnicity, (2) whether
Table II
Selection criteria
Inclusion criteria
1. Able to give written informed consent
2. Aged 18 to 65 y
3. SDE falling into 1 of 3 groups:
- White (white British, white Irish, or any other white background)
- Black/black British (black Caribbean, black African, or any other black background)
- Asian/Asian British (Asian Indian, Asian Pakistani, Asian Bangladeshi, or any other South Asian background)
4. Hypertensive as defined by:
-Monotherapy
- Treatment-naive patients:
Daytime average SBP ≥135 mm Hg or DBP ≥85 mm Hg
Using ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) (validated device based on an average of 10 readings)
- Treated patients:
Daytime average SBP ≥135 mm Hg or DBP ≥85 mm Hg
Using ABPM or HBPM (validated device based on an average of 10 readings), if:
Likely to achieve control on a study drug while being willing and able to complete 2-4 wk washout
- Dual therapy
- Treated (with 1–3 antihypertensive agents):
Daytime average SBP 135-200 mm Hg and/or DBP 85-110 mm Hg
Using ABPM or HBPM (validated device based on an average of 10 readings)
Exclusion criteria
a. Inability to identify with one of the predefined ethnic groups, eg, admixed origin
b. Pregnant or breastfeeding women
c. Known or suspected secondary hypertension
d. Significant sensitivity or contraindications to study medicines
e. Concomitant lithium or variable-dose non-steroidal anti-inflammatory drugs (NSAID) use
f. A requirement to take any of the study drugs continuously, eg, ACEi and heart failure
g. Clinically significant hepatic impairment
h. Clinically significant kidney impairment
i. Concurrent clinical trial participation (systemically vasoactive medicines or drugs known to interact with the study medicines)
j. Patients deemed unsuitable by the investigator on clinical grounds, eg, patients in atrial fibrillation
SDE: self defined ethnicity; SBP: systolic blood pressure; DBP: diastolic blood pressure; NSAID: non-steroidal anti-inflammatory drugs; ACEi: angiotensin converting enzyme inhibitors.
a b
YES
YES
YES
YES
YES NO
NO
AIM HY INFORM Clinical Trial 
Approx. 1320 patients 
MONO-THERAPY STUDY 
Approx. 660 patients (220 per ethnic group)
DUAL-THERAPY STUDY 
Approx. 660 patients (220 per ethnic group)
Newly diagnosed hypertensive 
APBM ≥ 135/85 mmHg
On NO hypertensive medication
Patients taking hypertensive 
medication who are suitable 
and willing to washout
Established Hypertension 
on 1-3 hypertensive medications 
AND BP ≥135/85 and/or ≤200/110 mmHg
Patient can be washed out
(Office BP <160/100 mmHg)
Minimum 2 week washout
Baseline parameters, OMICS*, Physiology, Haemodynamics, ABPM @ CRFA^ Baseline parameters, OMICS*, Physiology, Haemodynamics, ABPM @ CRFA^
Randomisation (open label) – Monotherapy rotation
Ensure consented to Dual-Therapy 
A - Amlodipine
C - Chlortalidone B - Lisinopril
5 mg 
10 mg 
Wk 1 2 8
Amlodipine
10 mg 
20 mg 
Wk 1 2 8
Lisinopril
25 mg 
8 weeks
Wk 1 8
Chlortalidone
8 weeks
8 weeks
8 weeks8 weeks
8 weeks
A - Amlodipine
B - Lisinopril
20 mg + 25 mg 
Wk 1 8
5 mg + 20 mg 
Wk
1 8
5 mg + 25 mg 
Wk
1 8
A - Amlodipine
C - Chlortalidone
C - Chlortalidone
25 mg + 10 mg 
Wk 1 8
D - Amiloride
B - Lisinopril
C - Chlortalidone 8 weeks
*OMICS = Metabolomic and Genomic analysis
** Dose up-titration in 1 or 2 weeks
^ CRF = Clinical Research Facility
Completed Mono-Therapy but fails 
to achieve target (<135/85 mmHg) –
may be eligible for Dual-Therapy
Ensure consented to Mono-Therapy
** 
**
Randomisation (open label) – Dual therapy rotation
Figure. Trial flowchart.
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previously identified biomarkers (ie, those derived from other cohorts,
eg, the United States) can predict the therapeutic response observed.
Further exploratory, tertiary objectives may be defined.Study population, treatment assignment, and randomization
The inclusion and exclusion criteria are listed in Table II. Hyperten-
sive adults aged between 18 and 65 years are eligible for inclusion
Table III
Selection criteria
Monotherapy
A. 1-2 wk of amlodipine 5 mg od followed by 6-7 wk of amlodipine 10 mg od
B. 1-2 wk of lisinopril 10 mg od followed by 6-7 weeks of lisinopril 20 mg od
C. Approximately 8 wk of chlorthalidone 25 mg od
Dual therapy
A. Approximately 8 wk of amlodipine 5 mg od and lisinopril 20 mg od
B. Approximately 8 wk of amlodipine 5 mg od and chlorthalidone 25 mg od
C. Approximately 8 wk of lisinopril 20 mg od and chlorthalidone 25 mg od
D. Approximately 8 wk of amiloride 10 mg od and chlorthalidone 25 mg od
Table IV
Outcome measures
Primary outcome measure
- Seated, automated, unattended, office SBP, measured approximately 8 wk after
each treatment
Secondary outcome measures
- All participants
- Seated, automated, office DBP
- Detailed SDE
- Core cardiovascular measurements
- Body composition assessment to determine lean and fat tissue mass
- Pulse wave analysis (carotid & femoral arteries) to derive pulse wave
velocity, central (aortic) waveforms, and central BP
- Echocardiography (including left ventricular mass and volume assessments)
- Dundee (3-min) step test (baseline only)
- Subgroups
- ABPM and/or HBPM
- Optional cardiovascular measurements
- Heart rate variability
- Regional arterial diameters
- cardiac output (CO) and stroke volume (SV) assessment (using a
noninvasive, inert gas rebreathing technique)
Tertiary outcome measures
- Hemodynamic and genomic measures
- Baseline demographics comparison
- Urine drug screening (random subgroup sample)
SBP: systolic blood pressure; DBP: diastolic blood pressure; SDE: self defined ethnicity;
ABPM: ambulatory blood pressure monitoring; HBPM: home blood pressure monitoring;
CO: cardiac output; SV: stroke volume.
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outlined. Treatment-naive individuals will be confined to the mono-
therapy arm. Those who have previously been treated/are being treated
with antihypertensive agents will be able to enter either arm provided
that they are able to undergo a washout of 2-4 weeks; if not, they will
be assigned to dual therapy.
Following allocation to a trial arm, subjectswill be randomized to a se-
quence of drugs (Figure) using an online system (https://www.
sealedenvelope.com). This requires the participant screening number, ini-
tials, date of birth, and SDE, along with the site name, confirmation of el-
igibility, and trial arm allocation. For those receiving monotherapy, 6
possible treatment sequences may be generated, as the intervention con-
sists of a 3-treatment, 3-period crossover: ABC, ACB, BAC, BCA, CAB, and
CBA. Where subjects are allocated dual therapy (a 4-treatment, 4-
period crossover), 4 possible treatment sequences exist: ABDC, BCAD,
CDBA, and DACB. In both instances, a Latin square balanced for first-
order carryover effects is deployed13; the randomization schedule will
also aim to have equal numbers of participants in each sequence.
Prescribed in an open-label manner, the treatments allocated to each
letter are detailed in Table III. Stable concomitant therapy for unrelated in-
dications is permitted provided that it does not have an antihypertensive
effect; dosemodifications for the trial drugs are not permitted. As this is a
pragmatic trial of licensedmedications, overall adherencewill be assessed
by urine drug screening for the studymedications in a randomly selected
subgroup of individuals (n = 50). Participants will also be asked to self-
report on compliance; where this falls below 75%, subjects may be with-
drawn at the discretion of the principal/chief investigator(s).Outcome measures
The primary outcome measure is seated, office, unattended systolic
blood pressure (SBP)measured 8weeks after each treatment period be-
gins. A validated, automated, brachial BP machine—the Omron HEM-
907—will be used to record 3 serial measurements.
Secondary and tertiary outcome measures are shown in Table IV.
Analysis of potential genetic polymorphisms associated with response
to antihypertensive treatment will be limited to those polymorphisms
previously linked to BP via genome-wide association studies.14 Prelimi-
nary retrospective analyses of randomized controlled trials evaluating
the efficacy of antihypertensive drugs suggest that many of these vari-
ants are also linked to antihypertensive drug response with relatively
large effect size; such effects may arise as a result of an overlap between
the homeostatic pathwaysmediating BP control and drug targets. Addi-
tionally, genomic variants known to be specifically associatedwith anti-
hypertensive drug response, published prior to the time of analysis, will
be evaluated.15 This will maximize the power of our trial to detect ge-
netic associations while avoiding the limitations of a candidate gene ap-
proach. The association with metabolites will be exploratory, using a
“metabolite-wide” association study approach,while also revisitingme-
tabolites that have previously been deemed significant in published
metabolite-wide association studies at the time of analysis.16,17Sample size calculation
To identify the effect of ethnicity upon response to the various treat-
ment options trialed with 98% power, 200 patients from each of the 3
ethnic groups, that is, 600 subjects per trial arm, will be required. This
assumes an SD for daytime systolic BP of 8 mm Hg, use of a global test
of interaction at the 5% significance level, and a single interaction of
4 mm Hg with others of 0 mm Hg. Should the single interaction be
3mmHg, the power is reduced to 81.3%. However, 4 mmHg is an effect
size approximately 50% of that reported for some of the agents to be
used in this trial when studied among black and white participants in
the United States.18
To allow for a 10% dropout rate, the trial will enroll 660 participants
per trial arm, with 220 subjects from each of the 3 ethnic groups. Re-
cruitment for each ethnic group will cease when 220 participants are
enrolled to ensure that equal numbers of patients are recruited. Sub-
group assessments are not powered, as these are exploratory measures.Statistical methods
The 2 crossover trials will be considered distinct entities for analytical
purposes; the results will be interpreted separately on an intention-to-
treat basis. The primary end point—automated, office SBP—will be ana-
lyzed using a linear mixed-effects model. This end point will serve as
the dependent variable, participant ID the random effect, with treatment
factors, treatment period, ethnic group, and treatment by ethnic group
the fixed effects. The global test of interaction, at a 5% significance level,
will be used to determine whether the treatment effect varies with eth-
nicity. In the event of a significant global test, the efficacy of individual
agents/treatments will be estimated with nominal 95% CIs; the assump-
tions of themodel will be assessed using graphical methods, for example,
a Q-Q plot and plots of residual versus fitted values. If any of the assump-
tions are violated, the dependent variable may be transformed to a nor-
mal distribution; if this fails to correct the distributional assumptions,
nonparametric methods will be used.
Analysis of secondary and tertiary outcomeswill be dependent upon
the volume of data acquired; assessments of this (and the appropriate
statistical methods) will be determined by the independent chair of
the Trial Steering Committee (TSC) (see below). A detailed statistical
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fore any interim analysis is performed.
Interim analysis and sample size reassessment
With limited prior data describing intraindividual SDs in SBP, the
multilevel nature of the trial design mandates an interim sample size
reestimation. Statistically robust and confined to an analysis of SD in
BP, this will be undertaken for each trial arm (monotherapy and dual
therapy) after approximately 50 participants have completed at least
2 treatment periods. Given the likelihood that recruitment to the 2
arms will differ, it is anticipated that the sample size reestimations are
unlikely to occur simultaneously.
Only results of the sample size reestimation will be communicated
to investigators; the details of any treatment effects will not be made
available.
Organization and funding
The trial, sponsored by Cambridge University Hospitals NHS Founda-
tion Trust and the University of Cambridge, is led by the Cambridge Clin-
ical Trials Unit at Cambridge University Hospitals NHS Foundation Trust.
Addenbrooke's Hospital, Cambridge, serves as the coordinating center,
whereas the Cambridge South (East of England) Research Ethics Commit-
tee provided a favorable ethical opinion for the protocol in October 2016.
A TSC consisting of experienced clinical investigators provides over-
all supervision for the trial, ensuring that it is conducted in accordance
with the protocol andGood Clinical Practice. Convening at regular inter-
vals and independently chaired (Prof Peter Sever), the committee as-
sumes overall responsibility for participant safety, consideration of
new information, and reviewing data, as specified in the TSC charter.
Part of the wider AIM-HY consortium, the AIM-HY INFORM trial is
funded by the Medical Research Council and British Heart Foundation.
The sponsors and funding organizations have no role in the study design,
study management, or data interpretation. The investigators (authors)
alone are responsible for these aspects of the study, as well as any data
analysis, the drafting and editing of manuscripts, and their final contents.
Current status
At present, 8 investigation centers are actively recruiting patients,
and it is anticipated that the trial will be completed by mid-late 2020;
the results will be reported approximately 6-9 months later. The first
patient was consented on 20 February 2017 and randomized on 6
March 2017; as of 15 May 2018, 318 patients had been consented,
with 252 randomized. The study has been registered with the Web
site ClinicalTrials.gov (NCT02847338).
Commentary
Ethnicity influences BP status, at both an individual and population
level; epidemiological data from the United States demonstrate a
greater prevalence of hypertension among African Americans, along
with poorer BP control among this cohort of the population.19-22 How-
ever, data describing the prevalence of hypertension among the United
Kingdom's various ethnic groups are inconsistent. Some UK studies de-
scribe a greater prevalence of hypertension, and significantly higher
mean BP, in both Afro-Caribbean and South Asian populations when
compared to the indigenous white population.23,24 Other studies have
shown significant variations in BP data among subgroups of the South
Asian population, with some sections of this community reportedly
having lower BP readings than white adults; at various times, these dif-
ferences have been attributed to religion (eg, Muslim, Sikh, Hindu), na-
tion of origin (eg, India, Pakistan, Bangladesh), and cultural grouping
(eg, Gujarati, Punjabi).25-27 Furthermore, studies which consider
admixed populations are sparse despite the fact that this cohort of thepopulation is growing in size; more than 1 million people in the United
Kingdom identify as “mixed,”with 0.8% of the English andWelsh popu-
lation describing themselves as being “white-black Caribbean,” 0.6%
“white-Asian,” 0.3% “white-black African,” and 0.5% “other mixed.”8
The pathophysiology of hypertension also appears to vary between
ethnic groups. In theUK SouthAsian population, elevated sympathetic ac-
tivity, arising from an increased prevalence of central obesity and insulin
resistance, is believed to be causally related to BP, whereas “low-renin”
hypertension is commonly described among black adults, with the
resulting salt andwater retention a significant determinant of BP status.28-
32 In contrast, salt-sensitive hypertension is relatively infrequent in white
adults.31,32 Black patients are also reported to express variants of several
genes, most frequently a threonine to methionine substitution, T594 M,
affecting the renal tubular absorption of sodium and water.33 Phenotypi-
cally akin to Liddle syndrome, this pathophysiological mechanism is pri-
marily mediated via the renal tubular epithelial sodium channel.34
Treatment on the basis of these observations has resulted in the use
of diuretics in hypertensive adults with low plasma renin activity and
antagonists of the renin-angiotensin axis (eg, angiotensin-converting
enzyme inhibitors [ACEi], angiotensin II receptor blockers [ARBs], or β-
blockers) in individuals with higher plasma renin activity.35-38 In addi-
tion to this, the parallels to Liddle syndrome have led a number of au-
thors to advocate the use of amiloride among cohorts of black
patients, both in the UK and elsewhere, whereas the elevated sympa-
thetic activity observed among South Asians has been used to justify
ACEi, ARB, and β-blocker use in this group.28,39
Although data relating to Asians in the North American literature are
limited—andwhere it is available, “Asian” frequently equates to “Far East-
ern” (Chinese, Japanese, etc)40,41—results from several large US studies
provide someevidence of ethnic variation in response to antihypertensive
drugs.34,42-47 In broad terms, greater falls in BP are achievedwith thiazide/
thiazide-like diuretics in black subjects with hypertension when com-
pared to their white peers; conversely, ACEi are less effective in this co-
hort. In the Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial, patients on chlorthalidone achieved better BP control
than those receiving lisinopril or amlodipine. Those using lisinopril had
a greater risk for stroke (risk ratio [RR]: 1.40, 95% CI: 1.17-1.68), combined
cardiovascular disease (RR: 1.19, 95% CI: 1.09-1.30), and heart failure (RR:
1.30, 95% CI: 1.10-1.54) compared with those receiving chlorthalidone,
treatment differences which were far more pronounced in African
Americans when compared with whites.42 Furthermore, the Antihyper-
tensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial re-
searchers reported a higher risk of stroke in African American
hypertensive patients treated with lisinopril as opposed to amlodipine
(RR: 1.51; 95% CI: 1.22-1.86), an association which was not observed in
non–African Americans (RR: 1.07; 95% CI: 0.89-1.28).42 Subsequent
meta-analyses reiterate these findings, demonstrating no evident benefit
from ACEi in achieving diastolic blood pressure (DBP) goals for African
American hypertensive patients.48,49 Conversely, ACEi may offer substan-
tial benefits for African Americans with hypertensive renal disease; in the
African American Study of Kidney Disease and Hypertension, ramipril
slowed renal disease progression in African Americans irrespective of
whether proteinuria was present, more so than amlodipine or
metoprolol.50 However, demographic differences with the United King-
dom (eg, a large South Asian population, population “admixture,” first/
second-generation immigrants as opposed to a population resident for
2-3 centuries), along with variations in vascular risk, diet, and weight, re-
strict the utility of US data.
The evidence for differential responses to antihypertensive drugs on
the basis of ethnicity in theUnitedKingdom ismore limited,with an anal-
ysis from 203 African, 132 South Asian, and 4,368 white participants in
the UK arm of the Anglo-Scandinavian Cardiac Outcomes Trial perhaps
the most robust source of data.51 This sought to determine whether
there were ethnic variations in response to monotherapy using β-
blockers (atenolol) or calcium channel blockers (amlodipine) and then
to add-on therapy with a thiazide diuretic (bendroflumethiazide) or
107O. Mukhtar et al. / American Heart Journal 204 (2018) 102–108ACEi (perindopril). The degree of BP reduction achieved in black patients
receiving atenolol monotherapy was significantly lower when compared
to white patients; South Asian patients achieved an intermediate treat-
ment effect. Amlodipinemonotherapy resulted in similar BP-lowering ef-
fects across all 3 ethnic groups, as did the addition of bendroflumethiazide
to atenolol. However, the addition of perindopril to amlodipine resulted
in statistically significant BP differences;white patients achieved a further
1.7–mmHg fall in SBP (95% CI:−2.8 to−0.7 mmHg), black patients ex-
hibited a diminished response (SBP change:−0.8 mm Hg; 95% CI:−2.5
to+4.2mmHg), whereas South Asians demonstrated a greater response
(SBP change:−6.2 mm Hg; 95% CI−10.2 to−2.2 mm Hg).51
The AIM-HY INFORMtrial aims to optimizefirst- and second-line an-
tihypertensive therapies for the multiethnic population of the United
Kingdom. In doing so, it will refine the “black versus white” approach
embodied in the current NICE guideline and further codify the treat-
ment of hypertension. The systematic and robust trial data produced
will also compare the value of SDE against genetically defined ancestry
andmetabolomics, informing future studies in low- andmiddle-income
countries, where the utilization of existing generic drugs in a resource-
efficient manner is imperative.
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